1.Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper
disorders[J].. Lancet Neurol 2015;14:103-13
2.Ferenci P. Pathophysiology and clinical features of Wilson disease[J]. Metab Brain
Dis 2004;19:229-39
3.Gromadzka G, Schmidt HH, Genschel J, et al. p.H1069Q mutation in ATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson's disease[J].. Mov Disord 2006;21:245-8
4.Zong Y, Kong X. Mutation analysis of 35 Wilson's disease pedigrees[J].. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2016;33:30-3
5.Schilsky ML. Wilson Disease: Diagnosis, Treatment, and Follow-up[J].. Clin Liver Dis 2017;21:755-67
6.Harada M. Management for acute liver failure of Wilson disease: Indication for liver transplantation. Hepatol Res2017; 47(4):281-2.
7.Kreymann B,Seige M,Schweigart U, et al. Albumin dialysis: effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: a new possibility for the elimination of protein-bound toxins. J Hepatol1999; 31(6):1080-5.
8.Litwin T, Dusek P, Czlonkowska A. Symptomatic treatment of neurologic symptoms in Wilson disease[J].. Handb Clin Neurol 2017;142:211-23
9.Litwin T, Dziezyc K, Karlinski M, et al. Early neurological worsening in patients with Wilson's disease[J].. J Neurol Sci 2015;355:162-7
10.Lorincz MT. Neurologic Wilson's disease[J].. Ann N Y Acad Sci 2010;1184:173-87
11.Lucato LT, Otaduy MC, Barbosa ER, et al. Proton MR spectroscopy in Wilson disease: analysis of 36 cases[J].. AJNR Am J Neuroradiol 2005;26:1066-71
12.Pfeiffenberger J, Kruse C, Mutch P, et al. The steady state pharmacokinetics of trientine in Wilson disease patients. European Eur J Clin Pharmacol,2018,https://doi.org/10.1007/s00228-018-2424-6
13.Merle U, Schaefer M, Ferenci P,et al.Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut 2007,56:115-20.
14.Roberts EA, Schilsky ML. Diagnosis and Treatment of Wilson Disease: An Update.Hepatology,2008,47(6):2089-111.
15.Dong Y, Shi SS, Chen S, et al. The discrepancy between the absence of copper deposition and the presence of neuronal damage in the brain of Atp7b(-/-) mice.METALLOMICS.2015,7(2):283-8.
16.Jason R. Copper on the brain. Nature Chemical Biology2018,14:638–41.
17.Felix B, Patricia S, Antonio G.M, et al. Modulation of copper accumulation and copper-induced toxicity by antioxidants and copper chelators in cultured primary brain astrocytes. Journal of Trace Elements in Medicine and Biology2015, 32:168–76.
18.Ferenci P, Stremmel W, Członkowska A,et al. Age,sex, but not ATP7B genotype effectively influences the clinical phenotype of Wilson disease. Hepatology.2019 69(4):1464-76.
19.Thomas GR, Forbes JR, Roberts EA, et al. The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 1995;9:210-7.
20.Cheng N,Wang H,Wu W,et al. Spectrum of ATP7B mutations and genotype-phenotype correlation in a large-scale Chinese patients with Wilson Disease. Clin Genet2017 92(1):69-79
21.European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol.,2012,56(3):671-85.
22.XE Yu, S Gao, RM Yang, et al. MR Imaging of the Brain in Neurologic Wilson Disease.AJNR Am J Neuroradiol.2019; 40:178-83.
23.Ala A, Walker AP, Ashkan K, et al. Wilson's disease. Lancet, 2007, 369(9559): 397-408.
24.Litwin T, Gromadzka G, Czlonkowska A, et al. The effect of gender on brain MRI pathology in Wilson’s disease[J]. Metab Brain Dis, 2013,28:69-75.
25.Walshe JM. History of Wilson’s Disease: 1912 to 2000. Movement Disorders, 2006, 21(2):142-147.
26.van Wassenaer-van Hall HN, van den Heuvel AG, Algra A, et al. Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. Radiology 1996;198:531-6
27.Ranjan A, Kalita J, Kumar S, et al. A study of MRI changes in Wilson disease and its correlation with clinical features and outcome. Clin Neurol Neurosurg 2015;138:31-6
28.Park HK, Lee JH, Lee MC, et al. Teaching NeuroIm ages: MRI reversal in Wilson disease with trientine treatment. Neurology 2010;74:e72
29.Niraj K, Deepak K. Teaching Video NeuroImages: Myoclonus as the presenting feature of Wilson disease. Neurology2019; 92:e1667-8.
30.Das M, Misra UK, Kalita J. A study of clinical, MRI and multimodality evoked potentials in neurologic Wilson disease. Eur J Neurol 2007;14:498-504
31.Seo GH,Kim YM,Oh SH, et al. Biochemical and molecular characterisation of neurological Wilson disease. J Med Genet2018; 55(9):587-93
32.Chen X,Xing S,Feng Y, et al. Early stage transplantation of bone marrow cells markedly ameliorates copper metabolism and restores liver function in a mouse model of Wilson disease. BMC Gastroenterol.2011; 11:75.
33.Merle U,Weiss KH,Eisenbach C,et al. Truncating mutations in the Wilson disease gene ATP7B are associated with very low serum ceruloplasmin oxidase activity and an early onset of Wilson disease. BMC Gastroenterol2010; 10:8.
34.O'Brien A,Williams R. Rapid diagnosis of Wilson disease in acute liver failure: no more waiting for the ceruloplasmin level? Hepatology2008; 48(4):1030-2.